(MENAFN- ABN Newswire)
In this segment of The Ellis Martin Report, Ellis speaks with Jerome Jabbour, the CEO of Matinas Biopharma (NYSE:MTNB). The company announced a research collaboration with ViiV Healthcare to evaluate formulation of antiviral drug candidates. Additionally, Mr. Jabbour will address Matinas' First Quarter 2019 Financial Results with an outlook toward the next 12 months.
To view the Video Audio, please visit:
http://www.abnnewswire.net/press/en/98116/MTNB
To view the release, please visit:
http://abnnewswire.net/lnk/540T2F2T
Matinas BioPharma ( NYSE:MTNB ) is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal ("LNC") platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.
The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
In addition, the Company's proprietary, disruptive technology utilizes lipid nano-crystal cochleates to encapsulate small molecules, nucleic acid polymers, vaccines and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
For more information, please visitwww.matinasbiopharma.comand connect with the Company on Twitter, LinkedIn and Facebook.
The Ellis Martin Report (TEMR) isan internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program.
Jenene ThomasJenene Thomas Communications, LLCT: (833) 475-8247E: ttp://www.matinasbiopharma.com The Ellis Martin ReportT: +1-310-430-1388E: WW: www.ellismartinreport.com
MENAFN1905201901110000ID1098543152
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.